granisetron: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
granisetron: clinical details
Prescribing considerations
- Confirm that the indication fits the selected patch licence: an adult receiving multi-day emetogenic chemotherapy whose swallowing difficulty complicates oral antiemetic use.
- Account for the patch’s gradual onset when coordinating antiemetic management.
- Counsel on adhesion, sunlight protection, external heat, washing and safe disposal.
- Safety and efficacy are not established for the selected patch in people under 18.
Contraindications and cautions
- Hypersensitivity to granisetron, another 5-HT3 receptor antagonist or a formulation excipient.
- Use caution with suspected subacute intestinal obstruction or gastric distension, pre-existing arrhythmia or conduction disease, serotonergic combinations, and renal or hepatic impairment.
- Remove the patch if a severe application-site or generalised skin reaction develops.
Monitoring
- Assess control of nausea and vomiting and the need for clinician-directed rescue treatment.
- Monitor bowel function and investigate abdominal pain or distension promptly.
- Observe for serotonin syndrome when serotonergic medicines are used concurrently.
- Consider ECG assessment when cardiac risk factors or interacting cardiac medicines are present.
- Inspect the application site and review clinically relevant liver-test abnormalities.
Clinical pharmacology
Granisetron is a highly selective 5-HT3 receptor antagonist with negligible affinity for several other serotonin and dopamine receptor subtypes. Transdermal absorption occurs slowly by passive diffusion. Metabolism is mainly hepatic, involving CYP1A1 and CYP3A4, and slow skin absorption prolongs the apparent terminal half-life.
Formulation and product differences
- The selected product is a matrix transdermal patch rather than an oral or injectable formulation.
- It offers non-oral delivery when swallowing is difficult but has a slower onset than oral granisetron.
- Patch-specific issues include adhesion, local skin reactions, sunlight protection, avoidance of external heat and residual active substance after removal.
granisetron preparations and strengths
Transdermal patch
Route: Transdermal
Strengths: 3.1 mg/24 hours
granisetron interactions
Tell the prescriber about all prescription, non-prescription and complementary treatments, particularly:
SSRIs and SNRIs
Combining serotonergic antidepressants with granisetron may increase the risk of serotonin syndrome.
Buprenorphine, opioids and other serotonergic medicines
The combination has been associated with serotonin syndrome and warrants clinical observation.
Phenobarbital
Enzyme induction may increase granisetron clearance and reduce exposure.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.